Who we are

CURIT Biotech Holding GmbH is a privately owned holding company and participates mainly in interesting medical bio-technology projects and startup companies.

Actual products of CURIT to be exploited are antibody-based bioassays for immune cytological or immune histochemical applications as well as an integration in in-vitro-diagnostic systems. Also we have developed antibody-based, targeted therapeutics for the treatment of various human diseases.

Univ. Prof. Dr. Dr. Stefan Barth

CEO

Stefan Barth, PhD, DMSc, Tier 1 South African Research Chair in Cancer Biotechnology

Prof. Dr. Dr. Stefan Barth holds responsible for research and development as well as all scientific topics within CURIT Biotech Holding.

He has studied biology at the Friedrich-Wilhelms-University in Bonn, Germany and did his PhD in 1994 (Dr. rer. nat.). In 1997 he received his DMSc (Dr. rer. medic.) at the University of Cologne. In 2001 he got his habilitation in Experimental Internal Medicine, also at the medical faculty of the University of Cologne.

In the time between 2000 and 2015, Prof. Barth was heading the Department of Pharmaceutical Product Development at the Fraunhofer Institute for Molecular Biology and Applied Ecology IME located in Aachen, Website-Texte-CURIT-Holding-08012015.docx Seite 1 von 5 Germany. From 2006 – 2015 he was appointed full professor at RWTH University and was head of Department of Experimentla Medicine and Immunotherapy at the Institute of Applied Medical Engineering at University Hospital RWTH Aachen.

Since April 2015 he awarded a Tier 1 South African Research Chair in Cancer Biotechnology under the South African Research Chairs Initiative (SARChI) of the Department of Science and Technology (DST) and administered through the National Research Foundation (NRF).

 

Jürgen Brink

CFO

Jürgen Brink is responsible for Finance/Law/Shareholdings within CURIT Biotech Holding.

Jürgen Brink is the managing director of the brink.corporate development GmbH management consultancy, which specialises in corporate strategy, mergers & acquisitions, and equity and loan financing.

Previously, Jürgen Brink worked for many years managing projects in acquisition and project financing, M&A transactions and IPO consultancy at a number of banks and an international auditing firm, before becoming Director of Corporate Development / M&A at one of Germany’s largest family-run companies. Here, he was responsible for expanding an investment portfolio of c. 500 businesses worldwide.